FDA expands talazoparib use in prostate cancer - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA expands talazoparib use in prostate cancer

The combination with enzalutamide reduced the risk of radiographic progression or death by 52% .

  • By

  • Mouj Hijazi

  • October 27, 2026

  • 3 min

Share

Original Source(s)

FDA expands talazoparib use in prostate cancer

  • by Mouj Hijazi

  • October 27, 2026

Related Content

3D holographic reconstruction and intraoperative navigation combined with CBL teaching in laparoscopic partial nephrectomy training for urology residents

Correction to: Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes

Impact of fluoroscopy technique on radiation time and surgical outcomes in supine percutaneous nephrolithotomy: a propensity score-matched analysis of intermittent versus live fluoroscopy